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ttp://dx.doi.org/10.1016/j.jmoldx.2016.06.004Use of next-generation sequencing to detect somatic variants in DNA extracted from formalin-ﬁxed,
parafﬁn-embedded tumor tissues poses a challenge for clinical molecular diagnostic laboratories
because of variable DNA quality and quantity, and the potential to detect low allele frequency somatic
variants difﬁcult to verify by nonenext-generation sequencing methods. We evaluated somatic variant
detection performance of the MiSeq and Ion Proton benchtop sequencers using two commercially
available panels, the TruSeq Amplicon Cancer Panel and the AmpliSeq Cancer Hotspot Panel Version 2.
Both the MiSeq-TruSeq Amplicon Cancer Panel and Ion Proton-AmpliSeq Cancer Hotspot Panel Version 2
were comparable in terms of detection of somatic variants and allele frequency determination using
DNA extracted from tumor tissue. Concordance was 100% between the panels for detection of somatic
variants in genomic regions tested by both panels, including 27 variants present at low somatic allele
frequency (<15%). Use of both the MiSeq and Ion Proton platforms in a combined workﬂow enabled
detection of potentially actionable variants with importance for patient diagnosis, prognosis, or
treatment in 49% (305/621) of cases. Overall, a combined workﬂow using both platforms enabled
successful molecular proﬁling of 96% (621/644) of tumor samples, and provided an approach for
veriﬁcation of somatic variants not amenable to veriﬁcation by Sanger sequencing (<15% variant allele
frequency). (J Mol Diagn 2016, 18: 842e850; http://dx.doi.org/10.1016/j.jmoldx.2016.06.004)Supported by the Princess Margaret Cancer Foundation.
Disclosures: None declared.In clinical molecular diagnostic laboratories, use of next-
generation sequencing (NGS) assays for detection of somatic
variants in solid tumors has great potential to improve patient
diagnosis, prognosis, and treatment based on identiﬁed tu-
mor variants.1 However, tumor molecular proﬁling by
NGS remains challenging in clinical diagnostics because of
the diverse types of tumor samples received by clinicalstigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orglaboratories and the resultant range of nucleic acid quality and
quantity derived from such samples. Most DNA samples used
in clinical testing for detection of solid tumor somatic variants
are obtained from formalin-ﬁxed, parafﬁn-embedded (FFPE)olecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Comparison of NGS Panels and Platformstumor tissue because of the ubiquitous use of FFPE for pa-
thology review.2 Quality of nucleic acid extracted from FFPE
samples is adversely affected by several factors, including,
but not limited to, tissue age, ﬁxation time, and tumor size.3
Nucleic acid quantity may be limited by both tumor sam-
pling method (such as ﬁne-needle aspiration4) and tumor
cellularity.1,5,6 As a result, a major challenge of testing FFPE
tumor samples by NGS-based assays for clinical diagnostics
is ensuring that most samples can be successfully analyzed
using clinically validated assays and method.
Somatic variants with impact on patient care may be pre-
sent at a wide range of variant allele frequencies (0% to
100%) because of tumor heterogeneity and clonal architec-
ture.7 Because of the range of variant allele frequencies, and
particularly the need to detect variants at low allele fre-
quencies (<15%), detection of somatic variants in tumors
necessitates high read depth in genomic regions of interest.8
Although NGS testing of nucleic acid extracted from tumor
samples using commercially available targeted gene panels is
readily accessible to clinical diagnostic laboratories, the
challenges presented by varying DNA quality and quantity
remain to be resolved. We addressed this challenge by
describing a clinical diagnostic approach to maximize testing
of FFPE tumor samples using two targeted NGS panels on
different sequencing platforms using different chemistries, the
TruSeq Amplicon Cancer Panel (ACP; Illumina, San Diego,
CA), analyzed on the MiSeq benchtop sequencer, and the
AmpliSeq Cancer Hotspot Panel Version 2 (CHP; Thermo-
Fisher, San Diego, CA), analyzed on the Ion Proton benchtop
sequencer. The NGS amplicon-based panels used in this
study cover similar sets of genes and are commonly used in
clinical molecular diagnostic laboratories for somatic variant
detection in FFPE tumor samples. We demonstrate in this
study that a combined workﬂow using both NGS panels and
platforms increases diagnostic yield of low quality or low
quantity DNA samples from FFPE tumor tissue. In addition,
we show that the use of two NGS platforms based on inde-
pendent sequencing chemistries9 allows comparison of results
from both NGS platforms to use as an orthogonal veriﬁcation
method for low allele frequency tumor somatic variants that
are not amenable to veriﬁcation by Sanger sequencing.
Materials and Methods
Tumor, Blood, and Cell Line Samples
The retrospective platform comparison portion of this study
used DNA extracted from 53 FFPE tumor (Supplemental
Figure S1) and matched blood samples (106 samples total),
which were received in the laboratory (Advanced Molecular
Diagnostics Laboratory, University Health Network, Toronto,
ON, Canada). DNA from all 53 cases (106 samples) was
analyzed using both the MiSeq-ACP (Illumina) and the Ion
Proton-CHP Version 2 (ThermoFisher). Two DNA samples
isolated from well-characterized HapMap cell lines, NA19878
and NA19240 (Coriell, Camden, NJ), were also tested on bothThe Journal of Molecular Diagnostics - jmd.amjpathol.orgplatforms. Variant calls obtained from a mixed dilution series
of the NA19878 and NA19240 cell lines ranging from 1:1 to
1:99 were used to determine variant allele frequency sensitivity
of the two platforms and panels. The prospective portion of this
study, assessing combined work ﬂow, included 644 consecu-
tive FFPE samples received in the laboratory between October
2014 and June 2015. Of the 644 samples, DNA from 418
tumors was analyzed by the MiSeq-ACP, 179 tumor DNA
samples were analyzed by the Ion Proton-CHP, 24 samples
were analyzed by both assays, and 23 samples had insufﬁcient
DNA to be sequenced on either platform.
DNA Extraction and Quality Assessment
For extraction of DNA from FFPE tumor samples, hema-
toxylin and eosinestained slides were prepared from FFPE
tumor and reviewed by board-certiﬁed pathologists to deﬁne
tumor regions and percentage of nucleated tumor cells
(median, 57%; range, 10% to 99%). Tumor regions were
macrodissected from 10 to 15 unstained slides for DNA
extraction, or punch cores (1 to 2  1-mm core) taken from
FFPE blocks. Collected FFPE tissue was deparafﬁnized
using xylene, followed by protein digestion using Proteinase
K, and DNA extracted using either standard phenol chlo-
roform methods for FFPE samples or the QIAamp Micro kit
(Qiagen, Germantown, MD).
DNA quality assessment was performed by quantitative
PCR, using the FFPE QC Template Standard DNA and QC
Primer Set (Illumina), with usable DNA samples having a
DCt value of <3.2. Each quantitative PCR (Invitrogen
Platinum SYBR Green; ThermoFisher) was performed on
the ABI 7900 Real-Time PCR machine (ThermoFisher).
DNA quantity was determined by Qubit quantiﬁcation using
the Qubit dsDNA HS Assay Kit (ThermoFisher).
Library Preparation and Sequencing
The TruSeq ACP (Illumina) includes 212 amplicons
covering regions of 48 genes and a total genomic region of
35.8 kb (Supplemental Table S1). Sixteen tumor and normal
pairs (ie, 32 samples total) were multiplexed per run. Library
preparation used 250 ng of DNA with the TruSeq Custom
Amplicon Kit (Illumina), followed by sequencing on the
MiSeq benchtop sequencing platform using the MiSeq Re-
agent Kit version 2 (Illumina) with paired end sequencing
with read lengths of 150 base pairs. For somatic variant
detection on the MiSeq-ACP, the following quality control
metrics (based on manufacturer’s recommendations) were
considered optimal: cluster density of 900 to 1200 k/mm2,
cluster passing ﬁlter percentage >90%, >90% of reads
greater than or equal to Q30 quality score, and total output
>4 Gb (Supplemental Figure S2).
The AmpliSeq CHP Version 2 (ThermoFisher) includes
207 amplicons covering regions of 50 genes and a total
genomic region of 22 kb (Supplemental Table S1). A total
of 16 to 20 tumor/normal pairs (ie, 32 to 40 samples total)843
Misyura et alwere multiplexed per run. Library preparation used 10 ng of
input DNA with the Ion AmpliSeq Kit Version 2.0 and
AmpliSeq Cancer Panel Version 2 primers (ThermoFisher),
followed by sequencing on the Ion Proton benchtop
sequencing platform using the P1 chip and 111- to 184-bp
read length. For somatic variant detection on the Ion
Proton-CHP, the following quality control metrics (based on
manufacturer’s recommendations) were considered optimal:
enrichment percentage, >90%; 20% to 30% polyclonal
beads; low-quality reads <20%; and overall usable reads
>55% (Supplemental Figure S3).
Data Analysis
For samples tested on the TruSeq Amplicon Cancer Panel,
FASTQ output ﬁles were analyzed by the MiSeq Reporter
software package version 2.4 (Illumina) and uploaded to
NextGENe version 2.3.1 (Softgenetics, State College, PA)
for alignment to reference genome hg19 (National Center
for Biotechnology Information Build 37) and variant call-
ing. For samples tested on the Ion Proton, FASTQ ﬁles were
downloaded from the Torrent Suite Browser v4.4 (Ther-
moFisher). Two independent software analysis programs
were used for alignment to reference genome hg19 (Na-
tional Center for Biotechnology Information Build 37) and
variant calling: Ion Reporter software version 4.2 (Ther-
moFisher) and NextGENe version 2.3.1 using default
variant ﬁlter settings: one allowable mismatched base; 50
allowable ambiguous alignments; seed of 30 bases; move
step of ﬁve bases; matching base 85%; hidden unmatched
ends; mutation percentage, 5% to 100%; and single-
nucleotide polymorphism allele count of 3. The
following variant calling settings were used in NextGENe:
median score threshold 20, called base number of each
read 25, trim or reject read 3, paired reads data,
maximum of uncalled bases 3, and bases with score 16.
Variants were ﬁltered with exclusion of variants with a
population frequency >1% in the 1000 Genomes database
(IGSR: The International Genome Sample Resource, http://
www.1000genomes.org, last accessed June 27, 2015) and
exclusion of synonymous variants. Missense variants, in-
frame insertions or deletions, and frameshifts in the re-
gions covered by each panel were included for analysis.
Calls with variant allele frequency of 5% (the laboratory
established limit of detection) and coverage of 500 were
considered to be of high enough quality to be interpreted
and potentially reported. Authenticity of individual calls
was manually assessed by a certiﬁed clinical laboratory
technologist to exclude potential artifacts, and to ensure real
calls were not missed because of poor quality (Supplemental
Figure S4).
All statistical analyses were performed in the R pro-
graming environment10 using custom scripts. Bland-Altman
analysis was performed as previously described,11 and bias
was calculated using the one-sample t-test with a null
hypothesis of 0.844Orthogonal Methods
Orthogonal non-NGS methods used for veriﬁcation of
variants included Sanger sequencing, custom ampliﬁcation-
refractory mutation system (ARMS) analysis,12 custom re-
striction fragment length polymorphism (RFLP) analysis,13
and/or a 279 custom laboratory-designed genotyping assay
using matrix-assisted laser desorption/ionization time of
ﬂight (MassArray, Agena Biosciences, San Diego, CA).14
Sanger sequencing was performed using a custom library
of primers covering variants of interest ampliﬁed using the
ProFlex PCR System (ThermoFisher), and sequenced on
3500XL Genetic Analyzer (ThermoFisher) using the Big-
Dye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher).
Results
Comparison of the MiSeq-ACP and the Ion Proton-CHP
Platforms
To compare variant calling results of the MiSeq-ACP to the Ion
Proton-CHP, we ﬁrst determined the bias, systematic error, and
the degree of agreement between the two methods, as assessed
using variant allele frequency values of 53 tumor normal pairs
on both platforms. Comparison used the Bland-Altman
method,11,15 a statistical analysis approach for comparing
quantitative and semiquantitative methods. There was no bias or
systematic error detectable, and the degree of agreement of 11%
was found between the Ion Proton-CHP and the MiSeq-ACP
(Figure 1A). Based on the linear regression analysis of the
concordant calls made by the two platforms, the two assays
demonstrated similar allele frequency measurements, as indi-
cated by the R2 value of 0.96 (Figure 1B). Therefore, both the
MiSeq-ACP and the Ion Proton-CHP demonstrated comparable
performance with respect to variant allele frequency calling.
In the context of Bland-Altman analysis, degree of
agreement and bias can be used as quantitative representa-
tions of precision and accuracy, respectively, provided
theoretical measurements are known a priori. We determined
precision and accuracy for detection of variants in the Hap-
Map cell lines NA12878 and NA19240 in a dilution series, as
described in Materials and Methods. The NA12878 and
NA19240 samples have been extensively sequenced and
documented in the GeT-RM Coordination Project (http://
www.cdc.gov/clia/Resources/GetRM, last accessed August
20, 2014), with information on high-quality variants (deﬁned
by GeT-RM as having been identiﬁed using two distinct
technologies) available for use in comparisons. Using Bland-
Altman analysis, the precision of variant allele frequency
calling was comparable between the MiSeq-ACP and the Ion
Proton-CHP, with differences from expected of 4.4% and
8.7% for the MiSeq-ACP and the Ion Proton-CHP,
respectively, based on cell line dilution series results
(Supplemental Figure S5). The accuracy of both platforms
was also comparable, as indicated by the calls made by the
MiSeq-ACP and the Ion Proton-CHP being 1.7% and 0.41%jmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 1 Variant allele frequency detection between the Ion Proton-Cancer Hotspot Panel (CHP) and the MiSeq-Amplicon Cancer Panel (ACP) was compared
according to Bland-Altman (A) and linear regression (B) analyses of concordant calls. The values for degree of agreement (black dashed lines), bias (black
dotted line), and systematic error (gray line) are shown, including the P values for the presence of bias and systematic error.
Comparison of NGS Panels and Platformsaway from the reference values, respectively, as calculated
from the dilution series (Supplemental Figure S5).
Detection and Veriﬁcation of Somatic Variants by
MiSeq-ACP and Ion Proton-CHP
Orthogonal methods used to verify variant results from NGS
included Sanger sequencing and laboratory-developed as-
says, including a custom matrix-assisted laser desorption/
ionization time-of-ﬂight recurrent mutation genotyping
assay for 279 variants (MassArray, Agena Biosciences), and
custom ARMS and RFLP assays for individual recurrent
mutations. Veriﬁcation of variants from NGS-based assays
using orthogonal methods presents challenges because of
limited regions or mutations tested by certain orthogonal
methods and the need for veriﬁcation of somatic variants at
low allele frequencies in tumors, which is difﬁcult to ach-
ieve below 10% to 15% allele frequency by methods such as
Sanger sequencing. Because of these limitations, variants
used to evaluate somatic variant detection for the MiSeq-
ACP and the Ion Proton-CHP were subdivided into two
subgroups based on variant allele frequency, a low allele
frequency subgroup (5% to 15% allele frequency) and a
high allele frequency subgroup (>15% allele frequency).
Only variants potentially useful for drug treatment decisions
and prognosis were veriﬁed in this study.
Detection of somatic variants by the MiSeq-ACP was
evaluated based on 749 variants detected in DNA extracted
from 442 FFPE samples. Variants were distributed across a
range of variant allele frequencies and genes (Figure 2, A
and B). Variants detected included single-nucleotide vari-
ants (n Z 719) and small insertions and/or deletions
(n Z 30) (Figure 2A), with 133 variants falling in the low
allele frequency subgroup (5% to 15% allele frequency) andThe Journal of Molecular Diagnostics - jmd.amjpathol.org616 in the high allele frequency subgroup (>15% allele
frequency) (Figure 2B). For veriﬁcation by non-NGS
orthogonal methods, 39 low allele frequency variants and
33 high allele frequency variants were selected. All 33 high
allele frequency variants detected by the MiSeq-ACP were
successfully conﬁrmed by an orthogonal method, but only
34 (87%) of 39 low allele frequency variants detected by the
MiSeq-ACP were able to be conﬁrmed by a non-NGS
orthogonal method (Table 1).
Similarly, detection of somatic variants by the Ion Proton-
CHP was evaluated based on 346 variants detected in DNA
extracted from 204 FFPE samples. Variants were distributed
across a range of variant allele frequencies and genes
(Figure 2, C and D). Variants detected included single-
nucleotide variants (n Z 329) and small insertions and/or
deletions (n Z 17) (Figure 2C), with 67 variants falling in
the low allele frequency subgroup (<15% allele frequency)
and 279 in the high allele frequency subgroup (>15% allele
frequency) (Figure 2C). For veriﬁcation by non-NGS
orthogonal methods, 26 low allele frequency variants and
22 high allele frequency variants were selected. All 22 high
allele frequency variants detected by the Ion Proton-CHP
were conﬁrmed by an orthogonal method; however, only
23 (88%) of 26 low allele frequency variants detected by the
Ion Proton-CHP were conﬁrmed using non-NGS orthogonal
methods (Table 1).
The availability of two independent NGS-based plat-
forms made it possible for us to compare the ability of an
alternative NGS platform to act as an orthogonal method for
veriﬁcation of somatic variants detected at low variant allele
frequency levels in tumor tissue (5% to 15% variant allele
frequency) by the initial NGS platform. We performed this
comparison using a retrospective set of 53 normal tumor
pairs (106 samples) with 190 variants tested by both NGS845
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Figure 2 A total of 749 and 346 variants detected by the MiSeq-Amplicon Cancer Panel (A and B) and the Ion Proton-Cancer Hotspot Panel (C and D) were
distributed across a range of genes and variant allele frequencies. Variants listed as other were detected in one of the following genes: RET, AKT1, CDH1, ERBB4, GNA11,
IDH2, KIT, MLH1, NOTCH1, RB1, ABL1, FGFR2, HRAS, IDH1, MPL, SMARCB1, SMO, GNAQ, STK11, CSF1R, FLT3, KDR, PDGFRA, FGFR1, HNF1A, PTPN11, and SMAD4.
Misyura et alplatforms, including 27 low and 163 high allele frequency
variants (Table 1). In comparison of high allele frequency
variants with variant allele frequency >15%, 100%
(nZ 163) of variants were detected by both NGS platforms
(Table 1), identical to the veriﬁcation rate by non-NGS
orthogonal methods for high allele frequency variants.Table 1 Concordance of Variant Detection between NGS and Non-NGS
Allele Frequencies
Variant allele frequency Orthogonal*/MiSeq-ACPy
5%e15% 34/39 (87)
>15% 33/33 (100)
*Orthogonal methods included ampliﬁcation-refractory mutation system, rest
desorption/ionization time-of-ﬂight panel (see Materials and Methods).
yFractions represent number of variants conﬁrmed by an orthogonal method/
methods. Percentages are given in parentheses.
ACP, Amplicon Cancer Panel; CHP, Cancer Hotspot Panel Version 2; NGS, next-g
846However, the conﬁrmation rate of 27 low allele frequency
variants (5% to 15%) was also 100% based on the results
from the two NGS platforms, in contrast to results of
veriﬁcation by non-NGS orthogonal methods where the rate
was 87% to 88% for variants between 5% and 15% variant
allele frequency. The two NGS platforms were able toOrthogonal Methods, for Variants Detected at Low or High Variant
Orthogonal/Proton-CHPy MiSeq-ACP/Proton-CHPy
23/26 (88) 27/27 (100)
22/22 (100) 163/163 (100)
riction fragment length polymorphism, or a custom matrix-assisted laser
the total number of variants detected by NGS and tested by orthogonal
eneration sequencing.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Comparison of NGS Panels and Platformsdetect and verify variants as low as 5% variant allele fre-
quency by concordance between the two platforms.
Furthermore, the two NGS platforms also demonstrated
100% concordance for 38 previously tested negative sam-
ples (data not shown), indicating that no platform-speciﬁc
false-positive variants were identiﬁed down to 5% variant
allele frequencies when comparing variant results between
the two platforms.
Integration of Ion Proton-CHP and MiSeq-ACP into a
Single Workﬂow Using DNA Quality and Quantity of
Clinical Samples
Variation in extracted nucleic acid quality and quantity from
FFPE tumor samples is a major challenge faced by clinical
diagnostics laboratories using NGS to detect somatic vari-
ants. Sample age and storage conditions have a signiﬁcant
effect on extracted DNA quality and quantity and affect
suitability for analytic methods,1,5,6 and yet are typically
outside the purview of the clinical laboratory receiving such
samples for analyses. In addition, the tumor size and
nucleated tumor cell content (tumor cellularity) in FFPE
regions from which DNA is extracted affect the somatic
variant allele frequency in analyses. To manage thisAll FFPE samples
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Figure 3 Integration of the MiSeq-Amplicon Cancer Panel (ACP) and the Io
workﬂow. Four hundred forty-two samples were sequenced by the MiSeq-ACP. Two
quantity and/or quality, including 24 samples that yielded inconclusive results by
>40 ng/mL*, 10e40 ng/mLy, <10 ng/mLz. DNA quality: DCt >3.2x and DCt <3.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgvariability and to optimize NGS testing for DNA derived
from FFPE samples, we developed a single workﬂow
combining both MiSeq (Illumina) and Ion Proton (Ther-
moFisher) NGS sequencing platforms to maximize data
quality and increase the overall diagnostic yield from FFPE
samples for tumor proﬁling (Figure 3). In our workﬂow,
samples were stratiﬁed according to quantity before the
quality assessment. Because of a lower acceptable limit of
DNA quantity and quality suitable for testing on the Ion
Proton, very low quantity samples (1 to 10 ng/mL) and low
quantity samples (10 to 40 ng/mL), or high quantity samples
(>40 ng/mL) with low quality values (quantitative PCR DCt
>3.2) are able to be tested by the Ion Proton-CHP. Of the
644 consecutive FFPE samples received during this study,
23 had insufﬁcient DNA for testing by either platform. Of
the remaining 621 samples, 442 met DNA quality/quantity
criteria for testing by the MiSeq-ACP. The remaining 179
samples did not meet DNA quality/quantity criteria for the
MiSeq-ACP but were successfully sequenced using the Ion
Proton-CHP. In addition, 24 samples that met quality and
quantity criteria for testing by the MiSeq-ACP but yielded
inconclusive results were also repeated successfully on the
Ion Proton-CHP. Therefore, inclusion of both the MiSeq-
ACP and Ion Proton-CHP into an integrated workﬂow 
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n Proton-Cancer Hotspot Panel (CHP) sequencing platforms into a single
hundred three cases were sequenced by the Ion Proton-CHP because of low
the MiSeq-ACP because of borderline quality and/or quantity. DNA quantity:
2{. n Z 179 (low quantity and/or quality).
847
Table 2 Summary of Variants, Including Potential Actionability,
Detected by the MiSeq-ACP and the Proton-CHP
Variable
Test method
MiSeq-ACP Proton-CHP Total
Total samples sequenced 442 203 621*
Samples with potentially
actionable variants
(classes 1e3A)
211 94 305
Total No. of variants by class
Class 1 103 52 155
Class 2 76 32 108
Class 3A 79 38 117
Other 245 110 355
*Twenty-four samples that failed or yielded inconclusive results on the
MiSeq-ACP were successfully sequenced on the Ion Proton-CHP.
ACP, Amplicon Cancer Panel; CHP, Cancer Hotspot Panel Version 2.
Misyura et alallowed successful analysis of 96% (621 of 644) FFPE
tumor samples.
Clinical Impact of the Combined MiSeq-ACP and Ion
Proton-CHP Workﬂow
To demonstrate the impact on clinical signiﬁcance and
diagnostic yield from use of an integrated workﬂow with
two NGS platforms for FFPE tumor proﬁling, the variants
detected by the combined workﬂow were interpreted for
clinical signiﬁcance, as described by Sukhai et al.16 Poten-
tial actionability of variants was determined based on
prognostic, diagnostic, predictive, or therapeutic informa-
tion conferred by those variants at the primary tumor site
provided. Overall, 380 potentially actionable variants (ie,
variant classes 1, 2, and 3A, as per Sukhai et al16) were
detected on the combined workﬂow, with 211 of 442
samples sequenced by the MiSeq-ACP containing 258
potentially actionable variants, and 94 of 203 samples
sequenced by the Ion Proton-CHP containing 122 poten-
tially actionable variants (Table 2). Overall, the combined
workﬂow detected at least one potentially actionable
somatic variant in 49% (305 of 621 samples) of tested FFPE
tumor samples.
Discussion
We evaluated the combined use of two targeted NGS gene
panels of similar gene content, designed for molecular
proﬁling of solid tumors, to detect variants of clinical
importance for oncology: the 50-gene CHP designed for the
ThermoFisher (Ion Torrent PGM, Ion Proton) benchtop
sequencers and the 48-gene ACP designed for the Illumina
(MiSeq, NextSeq 500) benchtop sequencers. Both NGS
panels and platforms as used in this study demonstrated
comparable performance in detection of somatic variants
from DNA samples extracted from FFPE tissue across
multiple genes and a wide range of variant allele848frequencies. This comparability information is useful for
clinical laboratories considering choice of NGS platforms
and making decisions about implementing NGS for somatic
variant testing, as most clinical diagnostic laboratories
validate and use only one NGS platform because of work-
load and cost demands to maintain more than one NGS
platform in a clinical diagnostic laboratory setting.
In our laboratory, we ﬁrst established the 48-gene ACP
on the Illumina sequencers as our primary somatic tumor
molecular proﬁling assay, and for this historical reason used
the Illumina ACP assay as the primary test in our combined
workﬂow (Figure 3). Our laboratory subsequently estab-
lished the 50-gene CHP on the ThermoFisher sequencers,
speciﬁcally to meet the need to test samples with lower
DNA quality and quantity, as described in Results. Because
the library preparation without automation and data analysis
steps of the Ion Proton-CHP platform were more labor
intensive than the MiSeq-ACP (Supplemental Table S2 and
Supplemental Figure S4), high quality/quantity samples in
this study were ﬁrst sequenced using the MiSeq-ACP, with
the Ion Proton-CHP used for reﬂex testing. Although most
clinical laboratories may not establish and maintain two
NGS platforms, there are insights from our study that are
relevant to clinical somatic variant analysis. The combined
workﬂow using the two NGS panels/platforms maximized
clinical impact of tumor molecular proﬁling by managing
potential limitations in quantity and quality of DNA
extracted from FFPE tissue samples received for routine
molecular diagnostic testing. As well, the availability of two
NGS platforms using independent sequencing chemistries
was useful for variant conﬁrmation in cases with multiple
variants, and for validation of large panels where single-
gene orthogonal testing methods are not available or are
prohibitively costly. In addition, use of two similar NGS
panels on different sequencing platforms enabled veriﬁca-
tion of 100% (n Z 27) potentially clinically important
somatic variants in the 5% to 15% variant allele frequency
range, which were problematic to verify by non-NGS
methods, such as Sanger sequencing.17
Orthogonal methods, such as Sanger sequencing, are
often used to verify a discordant result; however, the dif-
ferences in bioinformatics algorithms are often ignored as a
source of discrepancies. For the Ion CHP-Proton platform,
using two separate bioinformatics analyses (Ion Reporter,
NextGENe) to ensure high quality of data was determined to
be necessary at the expense of increasing the overall post-
sequencing results review time and cost (Supplemental
Figure S4). The data for each run were examined by a
certiﬁed technologist before interpretation of results to
identify potential artifacts, and to ensure real calls of lower
quality were not missed (Supplemental Figure S4). As a
result of manual review, the decision to use NextGENe as
an independent bioinformatics pipeline was made to resolve
minor differences between the bioinformatics pipelines. The
presence of low-frequency (<10% variant allele frequency)
deletions and insertions in the homopolymer regions wasjmd.amjpathol.org - The Journal of Molecular Diagnostics
Comparison of NGS Panels and Platformsevident in the Ion CHP-Proton data analyzed by NextGENe.
Interestingly, the same issue was not observed using the
stock Ion Reporter bioinformatics pipeline. As noted in
another validation study,18 the newer versions of the stock
Thermo Life bioinformatics pipeline are able to overcome
calling spurious homopolymer insertions/deletions. Using
two bioinformatics pipelines was necessary to ensure correct
calling of insertions/deletions by the Ion CHP-Proton
platform.
Based on our data, DNA extracted from 28% (nZ 179 of
644) of FFPE samples did not meet quality and quantity re-
quirements to be analyzed using the MiSeq-ACP. The addi-
tion of the Ion Proton-CHP to the workﬂow allowed our
laboratory to obtain potentially clinically important infor-
mation from additional 15% (nZ 94) of samples received for
analysis by NGS. Furthermore, 4% (nZ 24) of samples that
yielded inconclusive results on the MiSeq-ACP because of
low quality and/or quantity of DNA were successfully
sequenced on the Ion Proton-CHP (Figure 3). Recently, a new
system for sequencing on the Illumina platform, the TruSeq
Nano DNA Library Preparation Kit and the NeoPrep System,
has been developed to enable testing of low quantity DNA
samples on the Illumina NGS platform19; however, these re-
agents were not available at the time of this study.
Orthogonal testing is crucial for clinical diagnostic lab-
oratories because it allows one to provide variant veriﬁca-
tion for validation studies and it is used in situations where
the technical performance of a particular NGS test may not
be sufﬁcient to conﬁdently report the ﬁnal result without
conﬁrmation.20 For tumor molecular proﬁling by NGS
methods, this is particularly important for somatic variants
that occur at low levels in the tumor tissue (deﬁned in this
study as <15% allele frequency). Since potentially impor-
tant variants can be present at low variant allele frequencies
because of tumor heterogeneity and low tumor cellu-
larity,21,22 robust detection of such variants is essential in a
diagnostic setting. Sufﬁciently sensitive methods of somatic
variant detection, such as ARMS12 and RFLP,13 may be
available for recurrent mutation hot spot locations, such as
BRAF V60012 and KRAS G12,13 but do not have the
genomic region coverage capability of Sanger sequencing.
However, use of Sanger sequencing for veriﬁcation of
somatic variants is restricted by a lower limit of variant
detection of approximately 10% to 15% allele frequency.
Since the Ion Proton-CHP and MiSeq-ACP combinations
use independent sequencing chemistries,9 one of these two
sequencing platforms can be considered as an alternative
orthogonal method of variant conﬁrmation for variants
identiﬁed by the other NGS platform. For example, variants
present at low levels in somatic tissue, for which more
sensitive orthogonal methods (ARMS and RFLP) are not
readily available, can be conﬁrmed by an alternative inde-
pendent NGS platform. Furthermore, this approach allows
for conﬁrmation of cases with multiple variants or validation
of large panels also not easily achieved using single-
mutation tests or Sanger sequencing.The Journal of Molecular Diagnostics - jmd.amjpathol.orgOur results are in agreement with previous ﬁndings
regarding comparable performance of different NGS
assays and platforms. Several previous studies examined
the performance of multiple NGS platforms across a
diverse set of applications and found that sequence tech-
nologies manufactured by ThermoFisher and Illumina
produce comparable results.23e26 Sequencing platforms
from both ThermoFisher and Illumina have been evaluated
for potential uses in clinical microbiology,23 germline
variant detection,25 and prenatal testing.26,27 Our results
now provide evidence that both the MiSeq and Ion Proton
can be reliably used in an integrated workﬂow in a clinical
diagnostic setting for somatic variant detection and veri-
ﬁcation of low-level somatic variants on DNA extracted
from FFPE tumor samples.
Conclusions
The MiSeq and the Ion Proton sequencing platforms
showed equal performance in detection of somatic variants
in DNA derived from FFPE tumor samples using amplicon-
based commercial panels (ACP and CHP, respectively). The
Ion Proton-CHP was able to analyze low quantity/quality
DNA samples not suitable for sequencing on the MiSeq-
ACP. Overall in the clinical molecular diagnostic laboratory
setting, the combination of both NGS platforms allowed
successful analysis of 96% of DNA samples extracted from
FFPE samples while maximizing data quality and detection
of actionable somatic variants for patient prognosis, treat-
ment, and management. Furthermore, use of two NGS
platforms allowed veriﬁcation of multiple somatic variants
lower than the threshold for veriﬁcation by Sanger
sequencing (<15% somatic allele frequency). Our data thus
conﬁrm comparability of NGS platforms with different
chemistries, the utility of comparison of data from two NGS
platforms for variant veriﬁcation during assay validation,
and allowing ﬂexibility in testing of suboptimal material and
veriﬁcation of multiple variants of low allelic frequency for
somatic testing.
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